<DOC>
	<DOCNO>NCT00030459</DOCNO>
	<brief_summary>RATIONALE : Palliative therapy may help patient advanced cancer live comfortably . It yet know palliative therapy effective without chemotherapy treat patient malignant mesothelioma . PURPOSE : Randomized phase II trial compare effectiveness palliative therapy without different chemotherapy regimen treat patient malignant mesothelioma .</brief_summary>
	<brief_title>Palliative Therapy With Without Chemotherapy Treating Patients With Malignant Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility palliative therapy alone versus palliative therapy mitomycin , vinblastine , cisplatin versus palliative therapy vinorelbine patient malignant mesothelioma . - Determine quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize one three treatment arm . - Arm I : Patients receive palliative therapy alone comprise non-chemotherapeutic therapy ( e.g. , radiotherapy , painkiller , steroid , relaxant , special pain relief technique ) . - Arm II : Patients receive palliative therapy arm I chemotherapy comprise mitomycin IV ( course 1 , 2 , 4 ) , vinblastine IV , cisplatin IV 4 hour day 1 . Chemotherapy repeat every 21 day total 4 course . - Arm III : Patients receive palliative therapy arm I chemotherapy comprise vinorelbine IV 5 minute weekly week 1-6 9-14 . Quality life assess baseline patient ; week 3 , 6 , 9 , 12 arm I ; week 4 , 7 , 10 , 13 arm II ; week 3 , 6 , 10 , 13 arm III ; week 21 29 , every 8 week thereafter patient . Patients follow every 8 week . PROJECTED ACCRUAL : A total 60 patient ( 20 per treatment arm ) accrue study within 1 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Immunohistochemically cytologically confirm malignant mesothelioma Epithelial histological type Symptomatic pleural effusion allow treat controlled drainage , pleurodesis , pleurectomy Prior surgical resection allow stable progressive disease 2 CT scan measurement least 6 week apart PATIENT CHARACTERISTICS : Age : Not specify Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Not specify Renal : Not specify Other : Considered medically fit receive chemotherapy No disease prior malignancy would preclude study No clinical evidence infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy mesothelioma Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>